Literature DB >> 10750576

Chronic intravenous aminobisphosphonate therapy increases high-density lipoprotein cholesterol and decreases low-density lipoprotein cholesterol.

S Adami1, V Braga, G Guidi, D Gatti, D Gerardi, E Fracassi.   

Abstract

Nowadays, bisphosphonates are considered the drugs of choice for the treatment of several bone disorders. Their exact mechanism of action is not clear but recently it has been reported that the aminobisphosphonates inhibit cholesterol biosynthesis and that this might be relevant for their actions on bone osteoclasts. The study includes 87 postmenopausal women with moderate to severe osteoporosis. The patients were randomly assigned to intravenous (iv) infusion of 50 mg of the aminobisphosphonate Neridronate dissolved in 100 ml of saline solution every 2 months for a year (44 patients). The remaining 43 served as controls. At the time of each infusion blood samples were obtained for the evaluation of total cholesterol, triglycerides, high-density lipoprotein cholesterol (HDL-C) and low-density lipoprotein cholesterol (LDL-C), apolipoprotein A-I (Apo A-I), apolipoprotein B (Apo B), and total and bone alkaline phosphatase (AP). Free deoxypyridinoline (f-DPD) was measured in fasting urine specimens. In the control group no significant changes were observed throughout the study period for any of the biochemical variables. In the Neridronate-treated patients both bone AP and f-DPD excretion fell significantly by 15-20%. In these patients serum total cholesterol and serum triglycerides showed marginal decreases, which were occasionally significant. LDL-C and Apo B fell by 5-6% and these changes were statistically significant at most time points. Apo A-I and HDL-C rose progressively with time. At the 12th month, HDL-C rose 17-18% (p < 0.0001) above the baseline values. Similar findings were obtained in four postmenopausal women given high iv doses of Pamidronate or Alendronate. In conclusion aminobisphophonates, at least when given iv, induce remarkable and unexpected effects on lipid metabolism with a final profile that might be clinically relevant.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10750576     DOI: 10.1359/jbmr.2000.15.3.599

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  22 in total

Review 1.  The Pathogenesis and treatment of the valvulopathy of aortic stenosis: Beyond the SEAS.

Authors:  Sammy Elmariah; Emile R Mohler
Journal:  Curr Cardiol Rep       Date:  2010-03       Impact factor: 2.931

2.  Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).

Authors:  Sammy Elmariah; Joseph A C Delaney; Kevin D O'Brien; Matthew J Budoff; Jens Vogel-Claussen; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

3.  Myocardial infarction risk among patients with fractures receiving bisphosphonates.

Authors:  Cory B Pittman; Lisa A Davis; Angelique L Zeringue; Liron Caplan; Kent R Wehmeier; Jeffrey F Scherrer; Hong Xian; Francesca E Cunningham; Jay R McDonald; Alexis Arnold; Seth A Eisen
Journal:  Mayo Clin Proc       Date:  2014-01       Impact factor: 7.616

4.  Effects of growth hormone administration for 6 months on bone turnover and bone marrow fat in obese premenopausal women.

Authors:  Miriam A Bredella; Anu V Gerweck; Lauren A Barber; Anne Breggia; Clifford J Rosen; Martin Torriani; Karen K Miller
Journal:  Bone       Date:  2014-02-05       Impact factor: 4.398

5.  Lp-PLA2: inflammatory biomarker of vascular risk in multiple sclerosis.

Authors:  Zohara Sternberg; Alison Drake; Daniel S Sternberg; Ralph H B Benedict; Fan Li; David Hojnacki; Bianca Weinstock-Guttmann; Frederick E Munschauer
Journal:  J Clin Immunol       Date:  2012-01-13       Impact factor: 8.317

6.  Exercise and zoledronic acid on lipid profile and bone remodeling in ovariectomized rats: a paradoxical negative association?

Authors:  E Lespessailles; C Jaffré; G Y Rochefort; E Dolléans; C L Benhamou; D Courteix
Journal:  Lipids       Date:  2010-03-13       Impact factor: 1.880

7.  Therapeutic perspectives.

Authors:  Carmelo E Fiore; Pietra Pennisi; Marianna Tinè
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

8.  The link between osteoporosis and cardiovascular disease.

Authors:  Ghada N Farhat; Jane A Cauley
Journal:  Clin Cases Miner Bone Metab       Date:  2008-01

9.  Ectopic and serum lipid levels are positively associated with bone marrow fat in obesity.

Authors:  Miriam A Bredella; Corey M Gill; Anu V Gerweck; Melissa G Landa; Vidhya Kumar; Scott M Daley; Martin Torriani; Karen K Miller
Journal:  Radiology       Date:  2013-07-16       Impact factor: 11.105

Review 10.  Regression of vascular calcification in chronic kidney disease - feasible or fantasy? a review of the clinical evidence.

Authors:  Oscar Leonard; Jonas Spaak; David Goldsmith
Journal:  Br J Clin Pharmacol       Date:  2013-10       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.